[Breast-conserving therapy in breast cancer].
The combination of lumpectomy, axillary node treatment and radiotherapy of the breast is the base of breast-conserving therapy. This combination of surgery and radiotherapy is now accepted as a standard treatment option for unifocal, non inflammatory lesion less than 3 cm. The widespread use of mammography to detect infraclinic breast carcinoma leads to a significant increase in the proportion of breast conserving treatment. Neoadjuvant therapeutics (chemotherapy, radiotherapy and hormonotherapy) can extend the standard indication to breast carcinoma larger than 3 cm. The standard definition is also modified by sentinel node biopsy, oncoplastic techniques and stereotactic surgery with satisfactory cosmetic results. The risk of local recurrence, particularly the margins, must be evaluated whatever the surgical treatment optimizing oncologic management.
Service de chirurgie générale et sénoloqique, Institut Curie, 26 rue d'Ulm, 75005 Paris. anne.marcollet@curie.net
Anne
A
Marcollet
Virginie
V
Doridot
Claude
C
Nos
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy*; D002277:Carcinoma / Q000628:therapy; D017115:Catheter Ablation; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D016462:Mammaplasty; D008408:Mastectomy / Q000145:classification; D015412:Mastectomy, Segmental; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D021701:Sentinel Lymph Node Biopsy; D013238:Stereotaxic Techniques
D018931:Antineoplastic Agents, Hormonal